emia. First described by Elliot 1 in 1895 and characterized as a clinical entity by Warren and Eberhard 2 in 1935, MVT makes up 5% to 15% of all acute mesenteric ischemia. 3-s Despite modern diagnostic tools and methods, delay in diagnosis is frequent and contributes to the 15% to 40% mortality rate reported in the literature. 6-9 The primary reasons for delay in diagnosis are the nonspecific abdominal signs and symptoms of MVT despite progressive or advanced disease.
The increasing use of computed tomography (CT) and ultrasonography in the evaluation of abdominal disease has facilitated diagnosis of MVT and sparked interest in an earlier and more aggressive surgical treatment of this disease.l°-12 These imaging studies have also revealed MVT as incidental findings in patients without acute symptoms of bowel ischemia. Hence the spectrum of presentation for MVT is broad. Options for treatment may range from observation to urgent exploration with resection of infarcted bowel and possibly even venous thrombectomy. Anticoagulation is suggested by most authors.~3-~5 High recurrence rates and increased mortality rate remain significant problems) 617 Experience at any one institution with the management of MVT is limited; only case reports 1822 or small series 61°y exist in the literature dealing with this lethal form of bowel ischemia. Our study was designed to evaluate progress in diagnosis, management, and clinical outcome in a larger group of patients treated for MVT in the past 22 years at a tertiary referral center.
PATIENTS AND METHODS
We retrospectively reviewed the clinical course of 72 patients, 45 men and 27 women (mean age: 57.1 years, range: 23 to 81 years) , who were treated for MVT between January 1, 1972, and August 31, 1993 . This group represented 6.2% of 1167 patients treated for mesenteric ischemia during the same period at the Mayo Clinic. Patients who had MVT secondary to mechanical small bowel obstruction or volvulus were excluded. We also decided to exclude those patients who had MVT diagnosed at autopsy, because our pathologists had difficulty differentiating the diffuse postmortem mesenteric venous and arterial thrombosis from true MVT, which existed before death. Patients with symptoms of less than 4 weeks duration were classified as having acute MVT. Those with symptoms greater than 4 weeks duration but without bowel infarction or those with MVT diagnosed as incidental and clinically insignificant findings on abdominal imaging were classified as having chronic MVT. Primary MVT was defined as spontaneous, idiopathic thrombosis of mesenteric veins not associated with any other disease or etiologic factor. Patients with any condition known to predispose to MVT such as trauma, infection, or hypercoagulability were noted to have secondary MVT.
The following radiographic criteria for the diagnosis of MVT were established. Ultrasonography was positive for MVT, if thrombus or lack of flow was demonstrated in the superior mesenteric-portal venous system. Computed tomography was positive, if it demonstrated thrombus in the superior mesenteric vein, venous collateralization surrounding the occluded vein, or abnormal thickening of the wall of the ischemic bowel. Mcsenteric arteriography with venous phase was diagnostic for MVT, ifthrombus was demonstrated in the superior mesenteric vein. Additional findings included failure of arterial arcades to empty, a prolonged blush in the involved segment, and failure to visualize the superior mesenteric vein in an otherwise adequate study.
Statistical analysis was performed with Fisher's exact test or Pearson's x-square test to evaluate differences in categoric variables. Wilcoxon rank-sum test was used to test for differences in continuous variables. Kaplan-Meier estimate was used to assess survival and time to recurrence. Log-rank test was used to test for differences in survival between groups. Methods of treatment and outcome were analyzed and compared between patients with acute MVT from the earlier period of the study (1972 to 1983) and those treated during the last decade (1984 to 1993) . All values were expressed as mean + SEM. Statistical significance was accepted whenp < 0.05.
RESULTS
Seventy-two patients were identified with a diagnosis of MVT. Twenty patients were treated in the first period of the study (1972 to 1983) and 52 in the last decade (1984 to 1993). Fifty-three (74%) patients presented with acute MVT and 19 (26%) with the chronic form.
Cause. Fifty-seven (79%) patients had secondary MVT. Previous abdominal surgical procedure, hypcrcoagulable states, previous MVT, smoking, and history of deep venous thrombosis were the most prevalent associated conditions (Table I ). In the 30 patients with a hypercoagulable state, polycythemia vera was the most common disorder (11) . Other diseases included myeloproliferative disorders (six), antithrombin III deficiency (five), hyperfibrinogenemia (four), protein C deficiency (three), and protein S deficiency (two). Fifteen (21%) patients had primary, idiopathic MVT.
Acute mesenteric venous thrombosis. quadrants (71%). Abdominal distension and blood found during rectal examination were the most common findings on admission (Table III) . Peritoneal signs were present in 36% of the patients and fever in 25 %. The white blood cell count was elevated in half the patients, and lactate was abnormal in one third (Table III) . Platelet counts, fibrinogen levels, and coagulation studies at admission were generally within normal limits.
Diagnosis and radiographic imaging. Plain abdom-
inal radiographs were nonspecific and nondiagnostic. An ileus pattern was seen in 25 (71.4%) of 35 patients. Computed tomography was performed in 20 (38%) patients with acute MVT and demonstrated thrombus in the superior mesenteric vein (SMV) in 11 (55%) patients ( Fig. 1) . Thrombus was also noted in the portal vein in 35% and in the splenic vein in 35%. Abnormal bowel characteristics on CT (i.e., bowel wall thickening, pneumatosis, "streaky" mesentery) were found in 70% of the patients (Fig. 2) . The overall sensitivity of the CT scan to detect any abnormalities associated with acute MVT was 100%. Mesenteric arteriography with venous phase was performed in only seven (13%) patients. The presence of thrombus or nonfilling of the SMV was diagnostic of MVT in five of seven patients (sensitivity, 71%). One patient had sluggish filling of the SMV, and another had prolonged blushing in the region of the SMV. Ultrasonography with or without color duplex evaluations of the mesenteric veins were obtained in 10 patients. Thrombus or the absence of flow in the mesenteric veins were demonstrated in eight patients (sensitivity, 80%). Thirtyseven patients were diagnosed with MVT with radiographic techniques; 16 were diagnosed at the time of the operation. The median delay in diagnosis was 48 hours (mean, 83.1 + 17 hours). This delay in diagnosis did not change significantly over the last 22 years.
Treatment. Nineteen patients were treated without operation, with seven (37%) of these patients receiving anticoagulation. Thirty-four (64%) patients with acute MVT underwent abdominal exploration. Twenty-six were operated on at the Mayo Clinic, whereas eight had operations elsewhere and were transferred to us for further treatment. Among patients initially evaluated by us, 12 (46%) were operated on more than 48 hours after admission, and only six (23%) were operated on within 6 hours of admission. The diagnosis of mesenteric venous thrombosis was confirmed in all, although thrombus extended into the proximal superior mesenteric vein in only four (12%) patients (Fig. 3) . The arterial supply was intact with pulsatile flow palpable in the superior mesenteric artery in all but one patient. The jejunum and the ileum were affected most commonly (Fig. 4) In-hospital complications of treatment occurred in 55% of the patients (Table IV) . Short bowel syndrome as a result of extensive bowel resection developed in 40%. Five patients had p u l m o n a r y embolism after treatment. Only one of these five patients were given anticoagulants at the time of the (Fig. 5) . The long-term survival (as shown by Kaplan-Meier estimates) was only 36.4% (95% confidence interval: 23 to 57) at 3 years (Fig, 6 ). Twenty (38%) patients died of MVT.
Eight (15%) patients died of comorbid conditions: cancer (three); pulmonary embolus (two); liver failure (one); gastrointestinal bleeding (one); and multisystem organ failure (one). Those treated surgically and with anticoagulation had improved survival as did those who only underwent anticoagulalion, when compared with those patients who were observed without any treatment (Fig. 7) . The patient who underwent thrombectomy of the SMV died of recurrent MVT 2 weeks after the operation. Mesenteric venous thrombosis recurred in 19 (36%) patients. Most of the recurrences occurred during the same hospitalization or within 30 (74%) days. Anticoagulation alone had a higher recurrence rate than surgical procedure plus anticoagulation (71% vs 32%). 
Presentation. Nineteen (15 men and four women)
patients were diagnosed to have chronic MVT. The mean age was 58.5 + 2.5 years (range 42 to 78 years). Fifteen patients had history of vague, diffuse abdominal pain (Table II) . Four had no symptoms. The only abnormal laboratory study was the presence of mild leukocytosis in 44% (Table III) .
Diagnosis and radiographic imaging.
Computed tomography revealed changes characteristic of chronic venous occlusion in 13 of 14 patients (sensitivity, 92.9%). Angiography showed occlusion of the SMV with venous collateralization in seven of 10 patients (sensitivity, 70%) (Fig. 8) . Ultrasonography demonstrated cavernous transformation of the recanalized mesenteric veins with decreased or absent flow in five of eight patients studied (sensitivity, 62.5%).
Treatment. Three patients required surgical intervention for comorbid conditions (distal pancreatectomy for chronic pancreatitis, exploratory laparotomy for cancer and bleeding esophageal varices). Sixteen were treated without an operation. Nine of the 19 patients received anticoagulation.
Outcome. The mean length of follow-up was 13.7 _+ 4 months (range 1 day to 3.9 years). No patient's condition progressed to bowel infarction. Survival was higher when compared with that of the acute group (p = 0.041) (Fig. 6 ). The 30-day survival for this group was 94.4% (95% confidence interval: 84 to 100). Three patients died from complications of the comorbid conditions: pancreatitis, liver failure, and cardiomyopathy.
DISCUSSION
Mesenteric venous thrombosis continues to be an unusual condition. At our institution only 6.2% of all JOURNAL OF VASCULAR SURGERY 6 9 4 Rhee et al. = 12)  .............................. cases of mesenteric ischemia were due to venous thrombosis, and 17.9% of the patients with acute mesenteric ischemia had acute MVT. In other series M V T was reported to be the cause of bowel infarction in 5% to 25% of the patients with acute mesenteric ischemia as well. 3-5 Computed tomography and duplex ultrasonography have delineated a subgroup of patients with chronic MVT. Boley et al. 9 have characterized a group of patients with symptoms of abdominal pain of several weeks to months duration but without bowel infarction as having subacute MVT. They have characterized patients without symptoms or those with symptoms of portal hypertension such as gastrointestinal bleeding as having chronic MVT. For practical reasons we chose to combine the subacute and chronic groups as defined by Boley et al. 9 into our chronic group. We arbitrarily decided on 4 weeks, because this period seemed the most suitable to separate the acute from the chronic form of the disease. When we reviewed our data it was evident that if the patient remained without symptoms or had minimal abdominal pain for greater than 4 weeks, the chance of complications related to MVT decreased significantly. Indeed, none The number of patients with primary, idiopathic MVT is continuously decreasing. Increasing numbers of patients are now diagnosed with secondary MVT as the result of an increased awareness of disorders predisposing to MVT. 9'24 Comorbid states such as hypercoagulability, cirrhosis, splenomegaly, cancer, trauma, pancreatitis, or diverticular disease are responsible for most cases of MVT. Deficiency of physiologic anticoagulants such as antithrombin III, protein C, and protein S are known to be etiologic factors of MVT. 2528 Hematologic hypercoagulable states such as polycythemia vera, thrombocytosis, hyperfibrinogenemia, and myeloproliferative diseases are also associated with MVT 29 as are estrogen hormonal changes. 3°,31 Thirty (42%) patients in our study had a hypercoagulable state. In a classic autopsy study from 1948, Johnson and Baggenstoss a2 from the Mayo Clinic ideritified 99 cases of MVT. All but eight (12.4%) in their series had etiologic factors associated with the thrombosis. In a recent review of the literature, Abduet al. 6 found that 81% of all cases of MVT were secondary. In our series the prevalence of secondary MVT was also high (79%). Computed tomography was the most sensitive test in detecting thrombus in the mesenteric system in acute disease. When evidence for bowel ischemia or presence of venous thrombosis were considered together, sensitivity of the CT in showing an abnormality was 100%. It was also the most sensitive test to diagnose chronic disease. Mesenteric arteriography with venous phase demonstrated thrombus in 12 of the 17 patients studied. However, it continues to be the test of choice in patients with a clinical suspicion for arterial cause of mesenteric ischemia from arterial occlusion or insufficiency, or if the CT is equivocal or nondiagnostic of suspected venous thrombosis. However, the availability and use of these modern tests of imaging did not reduce the delay in diagnosis at our institution during the 22-year study period.
The decision to proceed with surgical exploration should be guided by clinical judgment. All patients with localized or diffuse peritonitis require exploration (Fig. 9) . The radiographic findings of MVT alone, however, do not necessarily mandate laparotomy. Indeed, with acute MVT the patients treated with anticoagulation alone had equivalent short-term survival when compared with those who had surgical treatment. One must acknowledge, however, that a selection bias undoubtedly existed. Laboratory studies were nonspecific (Table III) , and normal results should not deter surgical exploration. Preoperative laparoscopic 33 and endoscopic 34 evaluation of the small bowel have been used but with limited success in predicting bowel infarction in patients with MVT. Ninety-one percent of our patients who underwent exploration required bowel resection. If there was any question regarding the viability of the bowel after the resection, a second-look laparotomy after 24 hours was performed. We have used intravenous fluorescein to confirm viability of the bowel under Wood's light illumination with good predictive November 1994 value? s We did not believe that all patients required a second-look procedure, especially those who had localized disease and underwent resection with viable margins. In our series 41% of the patients underwent a second-look operation, and bowel resection was required in 100% of the patients. Although successful thrombectomy of the superior mesenteric vein has been described, a6,37 only one patient in our series underwent thrombectomy, but early rethrombosis occurred requiring later resection of additional bowel. We have not encountered a patient with a fresh proximal thrombus in the superior mesenteric vein without mechanical cause of the venous thrombosis (i.e., tumor) suitable for thrombectomy. Most patients with acute MVT have diffuse venous thrombosis with distal extension not suitable for venous thrombectomy. Anticoagulation significantly prolonged survival in our study (p = 0.043). Similar to Boley et al. 9 we begin administering intravenous heparin at the time of diagnosis, even during the operation, and maintain most patients on lifelong anticoagulation to decrease chances of recurrence. Effort should also be made to investigate the patient and his or her family for underlying coagulopathy and to treat any correctable abnormality.
In conclusion, similar to results of other series, our study also suggests that acute MVT is still a lethal disease with a 30-day mortality rate of 27% (Table  V) . Early mortality rate was 32% in the first period of our study and 24% in the last decade, but this improvement was not statistically significant. In spite of advances in imaging modalities, delay in diagnosis of acute MVT did not decrease significantly in the last decade. Computed tomography appears to be the most sensitive diagnostic test to confirm both acute and chronic MVT. For patients with acute MVT and peritonitis, early exploration with resection of the infarcted bowel and immediate anticoagulation affords the best prognosis. Those without peritonitis should undergo anticoagulation and be observed. However, the recurrence rate is high in spite of anticoagulation. For those with chronic MVT, survival is determined by the underlying disease.
